While aTyr Pharma insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know ...

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors cautious. See why ATYR stock is a Hold.

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight recommendation. Analyst Price Forecast Suggests 413.85% Upside As of ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday ...

Atyr PHARMA INC (NASDAQ:ATYR – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Atyr PHARMA in a report issued on Thursday ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for interstitial lung diseases, a Phase 3 trial in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...